Skip to main content

Advertisement

SpringerLink
Log in

Clinical Efficacy and Safety of Bathing with Chinese Medicine Taohong Siwu Decoction (桃红四物汤) for Treatment of Diffuse Cutaneous Systemic Sclerosis: A Randomized Placebo-Controlled Trial

  • Original Article
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Objective

To examine the efficacy and safety of bathing therapy with Taohong Siwu Decoction (桃红四物汤, TSD) in the treatment of early-stage, mild-moderate diffuse cutaneous systemic sclerosis (dcSSc).

Methods

This randomized, placebo-controlled trial enrolled 148 men and women (18–60 years) with dcSSc (disease duration 12 months) and baseline modified Rodnan skin score (MRSS) 10. Patients were randomized into a TSD group (71 cases bathing with TSD plus oral prednisone) or control group (71 cases bathing with placebo plus oral prednisone). Bathing (40 °C, 30 min) of the upper and lower limbs was carried out once daily for 12 consecutive weeks. The primary outcome measure was MRSS; secondary outcomes were Raynaud’s phenomenon (RP) score, quality of life (QOL), physician visual analogue scale (VAS), patient VAS, percent predicted diffusing capacity for carbon monoxide (DLCO), percent predicted forced vital capacity (FVC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level and overall treatment effect.

Results

The final analysis included 135 patients (control group, 68 cases; TSD group, 67 cases). Primary and secondary outcome measures after 2 weeks of treatment showed no improvement (versus baseline) in both groups, with no differences between groups. At 12 weeks, QOL, physician VAS, patient VAS, ESR and CRP were improved in both groups, but MRSS and RP score were improved only in the TSD group (all P<0.05). MRSS, RP score, QOL, physician VAS, patient VAS, ESR and CRP differed significantly between groups (all P<0.05). Meanwhile, the overall treatment effect was significantly higher in the TSD group than in the control group (P<0.05). Adverse events in the two groups were similar (P>0.05).

Conclusions

Bathing with TSD plus oral prednisone achieves better outcomes than oral prednisone alone in patients with dcSSc and is not associated with serious adverse events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pattanaik D, Brown M, Postlethwaite BC, Postlethwaite AE. Pathogenesis of systemic sclerosis. Front Immunol 2015;6:272.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Sticherling M. Systemic sclerosis-dermatological aspects. Part 1: Pathogenesis, epidemiology, clinical findings. J Dtsch Dermatol Ges 2012;10:705–718.

    PubMed  Google Scholar 

  3. Wielosz E, Dryglewska M, Majdan M. Serological profile of patients with systemic sclerosis. Postepy Hig Med Dosw (Online) 2014;68:987–991.

    Article  Google Scholar 

  4. Wang J, Assassi S, Guo G, Tu W, Wu W, Yang L, et al. Clinical and serological features of systemic sclerosis in a Chinese cohort. Clin Rheumatol 2013;32:617–621.

    Article  CAS  PubMed  Google Scholar 

  5. Chung L, Denton CP, Distler O, Furst DE, Khanna D, Merkel PA. Clinical trial design in scleroderma: where are we and where do we go next? Clin Exp Rheumatol 2012;30:S97–S102.

    PubMed  Google Scholar 

  6. Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999;42:1194–1203.

    Article  CAS  PubMed  Google Scholar 

  7. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351–1358.

    Article  CAS  PubMed  Google Scholar 

  8. Prey S, Ezzedine K, Doussau A, Grandoulier AS, Barcat D, Chatelus E, et al. Imatinib mesylate in sclerodermaassociated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. Br J Dermatol 2012;167:1138–1144.

    Article  CAS  PubMed  Google Scholar 

  9. Khanna D, Clements PJ, Furst DE, Korn JH, Ellman M, Rothfield N, et al. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebocontrolled trial. Arthritis Rheum 2009;60:1102–1111.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. LeRoy EC, Medsger TA, Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573–1576.

    CAS  PubMed  Google Scholar 

  11. Zhao D, Wang F. The study progress of TCM on systemic sclerosis. J Hubei Univ Nat (Chin) 2014;31:936–938.

    Google Scholar 

  12. Wang WL, Su YM, Yang RY, Zhang J, Xu Y. Followup efficacy of integrative Chinese and Western drugs on localized scleroderma with vitamine B6 and Xuefu Zhuyu Decoction. Chin J Integr Med 2005;11:34–36.

    Article  PubMed  Google Scholar 

  13. Yan XN, Han SR, Li WB, Li MH, Liu YT. Effects of Refu Yao on mice models with scleroderma of COL-I and COL-III. Chin J Dermatovenerol Integr Tradit West Med (Chin) 2011;10:353–355.

    Google Scholar 

  14. Wu L. Literature analysis of external treatment of traditional Chinese medicine (TCM) on scleroderma and exploration of drug laws. J Chengdu Univ Tradit Chin Med (Chin) 2014:12–36.

    Google Scholar 

  15. Geyer M, Muller-Ladner U. The pathogenesis of systemic sclerosis revisited. Clin Rev Allergy Immunol 2011;40:92–103.

    Article  PubMed  Google Scholar 

  16. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737–2747.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Zhang H, Liu T, Li F. A random, case-control study on the efficacy and safety of Weishi Bitong Xifang Fumigation for mild and moderate knee osteoarthritis patients. Int J Rheum Dis 2015;18:502–507.

    Article  PubMed  Google Scholar 

  18. Foocharoen C, Thinkhamrop B, Mahakkanukrauh A, Suwannaroj S, Netwijitpan S, Sripavatakul K, et al. Interand intra-observer reliability of modified Rodnan Skin Score assessment in thai systemic sclerosis patients: a validation for multicenter scleroderma cohort study. J Med Assoc Thai 2015;98:1082–1088.

    PubMed  Google Scholar 

  19. Milio G, Corrado E, Genova C, Amato C, Raimondi F, Almasio PL, et al. Iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol. Rheumatology (Oxford) 2006;45:999–1004.

    Article  CAS  Google Scholar 

  20. Georges C, Chassany O, Mouthon L, Tiev K, Marjanovic Z, Meyer O, et al. Quality of life assessment with the MOS-SF36 in patients with systemic sclerosis. Rev Med Intern 2004;25:16–21.

    Article  CAS  Google Scholar 

  21. Iudici M, Cuomo G, Vettori S, Avellino M, Valentini G. Quality of life as measured by the short-form 36 (SF-36) questionnaire in patients with early systemic sclerosis and undifferentiated connective tissue disease. Health Qual Life Outcomes 2013;11:23.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Hudson M, Thombs BD, Steele R, Panopalis P, Newton E, Baron M. Health-related quality of life in systemic sclerosis: a systematic review. Arthritis Rheum 2009;61:1112–1120.

    Article  PubMed  Google Scholar 

  23. Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, et al. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol 2005;32:832–840.

    PubMed  Google Scholar 

  24. Zheng XY, ed. Guiding principle of clinical research on new drugs of traditional Chinese medicine. Beijing: Chinese Medicine and Technology Publishing House; 2002.

    Google Scholar 

  25. Khanna D, Clements PJ, Postlethwaite AE, Furst DE. Does incorporation of aids and devices make a difference in the score of the health assessment questionnairedisability index? Analysis from a scleroderma clinical trial. J Rheumatol 2008;35:466–468.

    PubMed  Google Scholar 

  26. Wan L, Liu J, Huang CB, Wang Y, Chen X, Zhang WD, et al. Xinfeng Capsule for the treatment of rheumatoid arthritis patients with decreased pulmonary function—a randomized controlled clinical trial. Chin J Integr Med 2016;22:168–176.

    Article  PubMed  Google Scholar 

  27. Muangchan C, Harding S, Khimdas S, Bonner A, Baron M, Pope J. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group. Arthritis Care Res (Hoboken) 2012;64:1405–1414.

    Article  CAS  Google Scholar 

  28. Yang H, Lyu J, Huang LP, Yan YL, He XP. Effects of safflower decoction on the expression of skin vascular endothelial growth factor in mouse with scleroderma. Rheumat Arthritis (Chin) 2014;3:26–30.

    Google Scholar 

  29. Han L, Bian H, Ouyang J, Bi Y, Yang L, Ye S. Wenyang Huazhuo Tongluo Formula, a Chinese herbal decoction, improves skin fibrosis by promoting apoptosis and inhibiting proliferation through down-regulation of survivin and cyclin D1 in systemic sclerosis. BMC Complement Altern Med 2016;16:69.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Wu T, Chu H, Tu W, Song M, Chen D, Yuan J, et al. Dissection of the mechanism of traditional Chinese medical prescription—Yiqihuoxue formula as an effective antifibrotic treatment for systemic sclerosis. BMC Complement Altern Med 2014;14:224.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunology and Rheumatology, Gansu Provincial Hospital, Lanzhou, 730000, China

    Jing Zhou, Dong Yang, Shu-hong Zhou, Jin-ping Wang & Shu-lan Wang

  2. Department of Traditional Chinese Medicine, Gansu Provincial Hospital, Lanzhou, 730000, China

    Yue-shu Liu

Authors
  1. Jing Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dong Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shu-hong Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jin-ping Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yue-shu Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shu-lan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shu-hong Zhou.

Additional information

Supported by the Administration of Traditional Chinese Medicine of Gansu Province in China (No. GZK-2012-66)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, J., Yang, D., Zhou, Sh. et al. Clinical Efficacy and Safety of Bathing with Chinese Medicine Taohong Siwu Decoction (桃红四物汤) for Treatment of Diffuse Cutaneous Systemic Sclerosis: A Randomized Placebo-Controlled Trial. Chin. J. Integr. Med. 24, 185–192 (2018). https://doi.org/10.1007/s11655-017-2954-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-017-2954-2

Keywords

Search

Navigation